Demystifying Solid Tumor CAR-T: What Underpins Immunofoco's IPO Bid Amid Zero Revenue and Cash Flow Pressure?

Solid tumor CAR-T, is currentlyBiopharmaceuticalsThis frontier field holds the greatest potential within the sector and has also become a highly sought-after sci-tech innovation concept among capital markets. As an emerging enterprise deeply rooted in this sector in China, Immunofoco has officially filed its prospectus with the Hong Kong Stock Exchange, making a final push to secure a listing on the Hong Kong stock market.

However, the glamour of a trending sector ultimately cannot conceal the underlying reality of the company's operations. Stripped of the filter of capital-fueled hype and the romanticized narrative surrounding its technology, numerous fundamental weaknesses of Immunofoco are gradually laid bare, revealing that this seemingly promising Sci-Tech IPO harbors multiple deep-seated risks.

No Commercialization Precedent in the Track, All-In Bet on a Single Pipeline

The capital market valuation of Immunofoco is entirely underpinned by two independently developed solid tumor CAR-T pipelines: IMC002 targeting CLDN18.2 and IMC001 targeting EpCAM. Among them, IMC002 serves as the company's sole core valuation pillar and is currently the CLDN18.2-targeted solid tumor CAR-T candidate drug with the most advanced clinical development progress in China, constituting the company's most critical technological asset at this stage.

Industry discourse has largely downplayed the most critical real-world limitations: as of February 2026, no solid tumor CAR-T product has yet secured regulatory approval or achieved commercial launch globally. Compared to hematologic CAR-T therapies, which are technologically mature with multiple products already in clinical application, solid tumor CAR-T remains in the technological exploration phase, representing an unproven and largely uncharted territory within the industry. All corporate R&D investments, valuation and pricing, and growth expectations are predicated on technical assumptions that lack market validation, rendering the underlying logic of this sector inherently uncertain.

From a clinical data perspective, the early-stage trials of IMC002 exhibit significant limitations. Publicly disclosed information in the prospectus indicates that the Phase I/IIa clinical trial for this product enrolled only 15 evaluable patients, representing an extremely small sample size. Although the trial featured a notable case of a single patient maintaining a complete response (CR) for over 70 weeks, data from an isolated case lacks population representativeness and cannot validate the consistency of the drug’s efficacy and safety across a large-scale patient population, rendering its reference value extremely limited.

Compared with early exploratory trials, the operational complexity and quality control standards for the ongoing Phase III pivotal clinical trial of IMC002 have been substantially elevated. This trial plans to enroll 150 patients with CLDN18.2-positive advanced gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma. However, in clinical practice, the target screening process for these patients is cumbersome, the positive detection rate is relatively low, and the inclusion criteria are stringent, making it highly prone to enrollment delays and trial progress falling short of expectations. Meanwhile, solid tumors universally present industry-wide challenges such as an immunosuppressive tumor microenvironment and antigen heterogeneity, which can readily lead to attenuated drug efficacy, variable safety profiles, and even trial termination.

More critically, the company's drug pipeline portfolio has an extremely low margin for error and exhibits a severe single-asset dependency. Aside from IMC002, which has advanced to Phase III clinical trials, another core candidate, IMC001, remains only in early-stage clinical trials. All other products under development are still in the preclinical research stage, leaving them several years away from commercialization. The company currently lacks a mature backup pipeline to mitigate risks, with its core development entirely hinged on IMC002. Should the development of this candidate encounter any setbacks, the company's core valuation would collapse immediately.

Zero Revenue, Sustained Cash Burn: Funding Chain on the Verge of Collapse

For unprofitable biopharmaceutical companies, relying on financing to support R&D and incurring periodic losses is a common industry norm. However, Immunofoco's current financial condition has exceeded the industry's reasonable fluctuation range, forming a high-risk business model characterized by an absence of commercialized revenue, sustained large-scale cash burn, and complete reliance on financing for survival, indicating a severe lack of financial robustness.

Since its establishment in 2020, the company has yet to achieve product commercialization, generating no revenue from self-developed drugs, which has resulted in a severely distorted revenue structure.

Data from the prospectus indicates that the company recorded revenue of RMB 3.36 million in 2024 and RMB 2.88 million in the first nine months of 2025. Nearly all of its revenue is derived from government subsidies, reflecting a lack of market-driven cash generation capability and the absence of fundamental prerequisites for independent and sustainable operations.

The scale of the company's losses continues to widen, with financial pressure mounting year over year. In 2024, the company reported a full-year net loss of RMB 71.31 million; for the first nine months of 2025, the net loss had already reached RMB 66.00 million, reflecting a 28.3% year-on-year expansion in losses. During the same period, R&D expenses increased by over 26% year-on-year. The sustained escalation in R&D investment has further accelerated cash burn, placing the company's financial strain at a high level among comparable unprofitable innovative biopharmaceutical enterprises.

Cash flow pressure constitutes the Company's most critical fundamental weakness at present. As of the end of September 2025, the balance of cash and cash equivalents stood at merely RMB 140 million, alongside RMB 14 million in short-term borrowings. Operating cash flows recorded continuous net outflows during the first nine months of 2025, with capital in a state of ongoing depletion. Cash on hand is only sufficient to sustain short-term operations, highlighting pronounced pressure on the continuity of the Company's funding chain.

From the perspective of capital operations, this Hong Kong listing is not a strategic initiative for corporate expansion, but rather a typical maneuver to extend its financial lifeline. Should the IPO fundraising fall short of expectations or post-listing refinancing be impeded, the company will directly confront the crisis of a severed capital chain and a complete suspension of clinical R&D. Even if the listing succeeds, the company will still require frequent financing to sustain operations over the coming years. Continuous equity dilution will steadily erode the interests of existing shareholders and undermine the stability of corporate governance.

The structural imbalance between revenue and expenditures further exacerbates financial risks. The prospectus discloses that the company's share-based payment expenses surged by 175% year-on-year in the first nine months of 2025. Against the backdrop of zero revenue and sustained massive losses, substantial team incentives and personnel expenses continue to tie up working capital, further accelerating cash burn. Consequently, multiple financial risks are compounding upon one another.

Full-Chain Outsourcing Subject to External Control, Dual Loss of Control Over Capacity and Costs

A stable supply chain system, standardized large-scale manufacturing processes, and production capacity reserves aligned with market demand constitute the three core pillars for cell therapy products to transition from clinical R&D to commercialization. Against this industry logic, Immunofoco’s industrialization support system has yet to take shape, with multiple critical shortcomings that severely limit its capacity for subsequent commercial deployment.

The supply chain for core raw materials is highly concentrated, leaving the company with virtually no risk mitigation capacity. The key lentiviral vector materials required for CAR-T product manufacturing currently rely entirely on a single CDMO outsourcing vendor. The company has neither established an independent large-scale production system nor secured any backup suppliers. With supply chain concentration at an extreme level, any capacity constraints, process fluctuations, pricing adjustments, or contract termination by the partner would result in a complete halt to clinical trials and subsequent commercial production, as no emergency contingency plans are in place.

Current production capacity is only sufficient for small-scale clinical trials and is entirely inadequate to support commercial demands. The company’s Suzhou manufacturing facility currently has an annual capacity of just 300 CAR-T patient doses, which can only satisfy the limited dosing requirements of ongoing clinical trials and falls significantly short of the requirements for large-scale commercial supply. Moreover, capacity expansion necessitates substantial capital investment. Against the backdrop of persistent corporate losses and constrained cash flow, scaling up production is difficult to execute, making it highly prone to the industry dilemma of “R&D breakthroughs, capacity shortfalls, and inability to commercialize.”

The low-cost manufacturing process heavily promoted by the company remains merely a theoretical projection and has not been empirically validated through mass production. Although the company claims that its proprietary FOCO-CAR process can substantially reduce production costs, this conclusion is derived solely from laboratory-scale theoretical calculations. Lacking support from large-scale production data or third-party verification reports, uncertainties persist regarding both process stability and cost-reduction efficacy, thereby failing to constitute a substantive commercial advantage.

Inadequate control over commercialization costs inherently constrains profit margins. The profitability of mature CAR-T products in China is achieved through cost management enabled by in-house manufacturing capacity and stable supply chains. In contrast, Immunofoco relies entirely on outsourced production across all stages. During the commercialization phase, the company must continuously bear substantial CDMO service fees and royalty payments. With rigid production costs remaining persistently high, profit margins are continuously squeezed, making it difficult to realize the high valuation thesis previously predicated on low-cost manufacturing processes.

Compounded by Fierce Competition and Market Access Barriers, the Profitability Model Has Completely Collapsed

Even setting aside upfront risks such as R&D failure, funding shortfalls, and supply chain disruptions, and assuming the core product successfully obtains regulatory approval for commercial launch, Immunofoco still faces multiple structural barriers to commercialization, rendering the overall profitability model untenable and severely constraining long-term growth prospects.

The structural contradiction between exorbitant pricing and the inclusive mechanism of public medical insurance results in extremely narrow market coverage. CAR-T products currently marketed in China generally maintain pricing at the million-yuan level, and the industry's high-cost, high-price attributes are difficult to overcome in the short term. Meanwhile, national medical insurance access policies continue to tighten the reimbursement threshold for exorbitantly priced innovative drugs, prioritizing affordability and inclusive therapies.Medical Products。IMC002 lacks support from large-scale real-world efficacy data, making medical insurance reimbursement listing extremely difficult. It can only cover a niche high-net-worth population, leaving the mass market largely untapped.

Intensified competition within the therapeutic track has led to a dual squeeze from homogeneous rivalry and cross-modal substitution. The once-scarce CLDN18.2 target has now evolved into a highly saturated market, with multiple leading companies, including Legend Biotech and CARsgen Therapeutics, advancing similar pipeline programs, driving homogeneous R&D competition to unprecedented levels. Meanwhile, alternative modalities such as antibody-drug conjugates (ADCs) and bispecific antibodies are emerging as disruptive alternatives to customized CAR-T therapies. Leveraging advantages such as off-the-shelf availability, elimination of patient-specific manufacturing, and lower costs, these technologies are further compressing the commercial viability of customized CAR-T products.

The company lacks a commercialization operational infrastructure, and its market implementation capability is severely inadequate. To date, it has not established independent teams for sales promotion, academic education, and patient services, leaving its overall commercialization strategy highly dependent on external agencies. Given the high technical barriers, limited clinical awareness, and substantial challenges in market cultivation associated with CAR-T therapies, the prolonged market education cycle and complex hospital access procedures will continue to decelerate the pace of commercial rollout.

The commercialization cycle for the product is lengthy, resulting in a prolonged state of continuous investment without revenue generation. According to the timeline disclosed in the prospectus, IMC002 is expected to file its marketing authorization application no earlier than 2027, while regulatory approval and market expansion will require several additional years. This model of sustained R&D expenditure without operational returns will persistently deplete the company's existing cash reserves, continually amplifying operational uncertainties.

Compliance Deficiencies Compounded by Capital Flight, Latent Risks Converge and Lie Dormant

Compared to overt R&D and financial risks, the latent governance and compliance issues at Immunofoco are more concealed and prone to sudden emergence, potentially becoming the core risk that could erode corporate valuation and market confidence post-listing.

The equity structure and team background inherently give rise to potential risks of related-party transactions. The prospectus indicates that Pengfu Shenzhen, an affiliate of the Fosun Group, is the company's second-largest shareholder, holding a 15.16% stake; the founders and core team members predominantly possess professional backgrounds within the Fosun ecosystem. The convergence of equity ties and shared personnel origins makes it highly likely that the company's core operations—including clinical trials, CDMO outsourcing, and academic collaborations—will involve substantial related-party transactions with the Fosun network, posing potential risks of non-arm's length pricing and the compromise of minority shareholders' rights and interests.

The concentrated exit of industry capital during the critical IPO window period sends a cautious market signal. From October to December 2025, during the crucial phase of the company's IPO sprint, multiple seasoned industry investors, including Changshu Shenggu High-Tech, Yueke Dongjiang Guohui, and Songhe Cell Fund, exited en masse, with their stakes taken over by emerging institutions. The bulk withdrawal of professional industry capital reflects the cautious stance of established institutions regarding the company’s R&D prospects, commercialization likelihood, and valuation potential.

Incomplete compliance formalities for leased premises and insufficient stability of core operational sites. Among the six properties leased by the Company in China, only one has completed compliance filing, while the remaining properties exhibit procedural deficiencies, posing a risk of administrative penalties. More critically, the leases for the Company’s core R&D laboratories and GMP production facilities in Shanghai and Suzhou will expire in 2028. Failure to secure successful renewals would directly lead to a suspension of R&D activities and disruption of production, thereby exerting a material adverse impact on the Company's operations.

No Track Record, No Certainty: This IPO Is Purely a Capital Gamble

Based on the publicly disclosed information in the prospectus and the objective realities of the industry, the market valuation of Immunofoco relies entirely on uncommercialized technological projections, small-sample clinical data, and theoretical cost advantages, lacking any substantive support from commercial performance or stable cash flow. Furthermore, the persistent losses, liquidity pressure, supply chain deficiencies, and compliance flaws faced by the company constitute objectively existing and unavoidable inherent operational risks.

From the perspective of the sector’s underlying logic, solid tumor CAR-T therapies have yet to achieve any globally successful commercialization, the industry’s technological pathways remain incompletely mature, and the outcomes of core pipeline R&D are highly uncertain. From the standpoint of current operations, the company lacks internal cash-generating capacity, faces continuous capital depletion, and its loss trajectory is difficult to reverse. From a long-term development perspective, multiple risks across R&D, industry, market, and corporate governance compound and mutually reinforce each other, completely eliminating any room for the company’s sustainable growth.

This Hong Kong IPO does not represent a valuation expansion for a high-quality sci-tech innovation enterprise, but rather a typical capital maneuver characterized by high speculation and a low success rate. At its current stage, the company lacks robust long-term investment value and exhibits only short-term speculative attributes driven by sector concept narratives.

Capital markets will always chase the growth narratives of frontier technologies, but conceptual storytelling can never ultimately replace realized performance and predictable returns. Stripped of the glamorous halo of the CAR-T sector, Immunofoco’s fundamentals are riddled with shortcomings and hidden risks, resulting in exceptionally high operational uncertainty. The future trajectory of the company’s valuation will depend entirely on the disclosure of clinical data, regulatory approval outcomes, and the progress of commercialization. (Produced by Zhitai)

       Demystifying Solid Tumor CAR-T: What Underpins Immunofoco's IPO Confidence Amid Zero Revenue and Financial Pressure?